Lingxin Kong

536 citations
21 papers · 375 indexed · h-index 12
Topics
Virus-based gene therapy research (4 papers)Herpesvirus Infections and Treatments (3 papers)Inflammatory Biomarkers in Disease Prognosis (3 papers)

In The Last Decade

Lingxin Kong

19 papers receiving 367 citations

Peers

Lingxin Kong
Comparison fields: 5 of 67
  • Molecular Biology 160
  • Oncology 142
  • Genetics 119
  • Epidemiology 63
  • Cellular and Molecular Neuroscience 48
Replace Kohzoh Imai with:
Kohzoh Imai Japan
Meirong Bai China
Samisubbu R. Naidu United States
Wenmin Zhang China
Debanjan Bhattacharya United States
Peijun Wang China
Charles Ashton United States
Pershang Farshi United States
Orie Nakamura Japan
Lingxin Kong relative to Kohzoh Imai Japan Kohzoh Imai's profile →
Citations per field
00.5×10×16.3×
Kohzoh Imai · 1×
Citations per year

Countries citing papers authored by Lingxin Kong

Since Specialization
Citations

This map shows the geographic impact of Lingxin Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingxin Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingxin Kong more than expected).

Fields of papers citing papers by Lingxin Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingxin Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingxin Kong. The network helps show where Lingxin Kong may publish in the future.

Co-authorship network of co-authors of Lingxin Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Lingxin Kong. A scholar is included among the top collaborators of Lingxin Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingxin Kong. Lingxin Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 3
3 3
4 0
5 0
6 17
7 7
8 1
9 16
10 30
11 54
12 22
13 3
14 12
15 41
16 8
17 31
18 28
19 23
20 53

About Lingxin Kong

Lingxin Kong is a scholar working on Complementary and Manual Therapy, Complementary and alternative medicine and Oncology, having authored 21 papers that have together received 375 indexed citations. Recurring topics across this work include Virus-based gene therapy research (4 papers), Herpesvirus Infections and Treatments (3 papers) and Inflammatory Biomarkers in Disease Prognosis (3 papers). The work is most often cited by research in Oncology (142 citations), Genetics (119 citations) and Complementary and alternative medicine (27 citations). Lingxin Kong has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Alfred I. Geller, Mei Sun, Xiaodan Wang, Guorong Zhang, Yang Du, Jie Tian, Courtney Holmes, Xiaodan Wang, David S. Goldstein and Guorong Zhang. Their work appears in journals such as Cancer Research, Journal of Agricultural and Food Chemistry and Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026